NCT05677334View on ClinicalTrials.gov

Combination of Henagliflozin and Continuous Subcutaneous Insulin Infusion in T2DM

PHASE4CompletedINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

October 30, 2024

Study Completion Date

October 30, 2024

Conditions
Type2diabetes
Interventions
DRUG

Henagliflozin

Combination therapy of Henagliflozin and Continuous Subcutaneous Insulin Infusion

DEVICE

Continuous Subcutaneous Insulin Infusion

Continuous Subcutaneous Insulin Infusion therapy alone

Trial Locations (1)

530021

First Affiliated Hospital of Guangxi Medical University, Nanning

All Listed Sponsors
lead

First Affiliated Hospital of Guangxi Medical University

OTHER